Every move below traces to a number or a voice from the study — the same groundedness standard we hold for client content.
1. Organise content by molecule, not just topic
Molecule-branded demand is 2.8M searches/month and the growth class; Mounjaro alone (1.87M) out-demands every generic cluster. A "weight loss injections" hub with molecule paragraphs is structurally outgunned by per-molecule authority pages that answer the real queries: eligibility, dosing, side effects, price, regain — per molecule, per journey stage.
2. Win the research layer — that's where conversion happens
Research carries ~2.8M monthly searches; transactional terms fewer than 2K. Providers already hold 61% of research visibility, but it is unevenly held — and the patient converts wherever their research concluded. Answer the questions the funnel actually asks (we hold the full ranked list, stage by stage).
3. Treat AI citations as a separate discipline
The reshuffle is measured, not hypothetical: NHS −13.9 points, NICE +5.4 from zero, telehealth 10× its share. What earns citations is structured, referenced, evidence-led content — the pattern the winners share. Build for it, then measure citation share the way you measure rankings (we do, monthly).
4. Own the regain conversation
The single most divisive axis in 79,000 snippets (+0.45 tirzepatide vs −0.34 semaglutide) and the decision driver for switchers — yet it is the thinnest content territory in the market. Honest maintenance-and-stopping content is unclaimed authority.
5. Watch the next wave — the study is a feed, not a snapshot
Retatrutide: 90K monthly searches before launch, aspiration-led register. Saxenda: collapsed. Categories like this reprice quarterly — the demand series, citation shares and perception axes here update as feeds, which is how this study is maintained.
Want the underlying evidence for any claim on these pages? Ask the study directly: the weight-loss chatbot answers only from this corpus — with quotes.